Compare FSV & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSV | BLCO |
|---|---|---|
| Founded | 1988 | 1853 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.0B |
| IPO Year | 2015 | 2022 |
| Metric | FSV | BLCO |
|---|---|---|
| Price | $154.92 | $18.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $210.67 | $18.55 |
| AVG Volume (30 Days) | 269.9K | ★ 410.0K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $7.43 | $7.45 |
| Revenue Next Year | $6.65 | $5.49 |
| P/E Ratio | $49.49 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $147.23 | $10.45 |
| 52 Week High | $205.99 | $18.92 |
| Indicator | FSV | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 71.47 |
| Support Level | $149.03 | $16.35 |
| Resistance Level | $158.41 | N/A |
| Average True Range (ATR) | 4.46 | 0.58 |
| MACD | -0.17 | 0.17 |
| Stochastic Oscillator | 50.23 | 88.55 |
FirstService Corp operates in two business divisions: FirstService Residential and FirstService Brands. FirstService Residential has service contracts to manage thousands of residential communities, including high-, medium-, and low-rise condominiums and co-operatives. FirstService Brands generates the majority of the company's revenue and provides property services to residential and commercial customers through the following brands: California Closets; Paul Davis Restoration; CertPro Painters; Pillar to Post; Floor Coverings International; College Pro Painters; and Service America. The company earns the majority of its revenue in the United States, with the remaining revenue generated in Canada.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.